Publications
46
Citations
261
Est. group size
~7
Recurring co-author estimate
Active years
31
Publishing since 1996
Typically publishes in teams of ~9 · 6% small-team papers (≤3 authors) · across 17 venues
- Supplemental Table S1. Full clinicopathologic characteristics of IVLBCL and DLBCL cases with cutaneous recurrence
Mendeley Data · 2026
- Supplemental Table S1. Full clinicopathologic characteristics of IVLBCL and DLBCL cases with cutaneous recurrence
Mendeley Data · 2026
- Systemic intravascular large B-cell lymphoma relapsing as an extravascular cutaneous large B-cell lymphoma after 8 years from initial diagnosis
JAAD Case Reports · 2026
- Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study
Blood · 2025
- Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma
Leukemia & lymphoma/Leukemia and lymphoma · 2025
- 808 | PHASE 1b/2 STUDY OF MAPLIRPACEPT (PF‐07901801), TAFASITAMAB, AND LENALIDOMIDE IN TRANSPLANT‐INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PARTICIPANTS
Hematological Oncology · 2025
- Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis
Current Oncology · 2024
- Incidence, characteristics and outcomes in relapsed and refractory CD20+ PTLD: An institutional retrospective cohort study.
Journal of Clinical Oncology · 2024
- Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study.
Journal of Clinical Oncology · 2024
- Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study
Clinical Lymphoma Myeloma & Leukemia · 2024
- ABCL-616 Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study
Clinical Lymphoma Myeloma & Leukemia · 2024
- Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor
Blood · 2024
- Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)
Blood · 2024
- Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report
AME Case Reports · 2023
- Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma
Blood · 2023
- Blood×14
- Journal of Clinical Oncology×5
- Hematological Oncology×4
- Clinical Lymphoma Myeloma & Leukemia×2
- Mendeley Data×2
- Beth Christian
Medicine · The Ohio State University
- David A. Bond
Medicine · The Ohio State University
- Narendranath Epperla
Medicine · The Ohio State University
- Kaitlin Annunzio
Medicine · The Ohio State University
- Timothy Voorhees
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile